Dr. Jennifer L. Baker is an Associate Professor at the University of Copenhagen and she is also affiliated with the Institute of Preventive Medicine in Frederiksberg, Denmark. She received her PhD in Nutrition from Cornell University. Thereafter she conducted her postdoctoral studies in Denmark. The focus of her research program is on the causes and short- and long-term consequences of childhood obesity. Her work has been conducted using data primarily from Danish sources, but also from the US and several Nordic countries. Her research has been supported by the NIH and is currently supported by the European Research Council and the Danish Council for Independent Research in Medical Sciences. She is an executive board member of the Childhood Obesity Task Force, which is part of the European Association for the Study of Obesity.
Matthias Blüher is Professor in Molecular Endocrinology at the University of Leipzig and has extensive practical experience in the treatment of patients with type 2 diabetes, obesity and endocrine disorders. He is also the Head of Collaborative Research Center “Obesity mechanisms” (SFB 1052) and one Coordinator of the federally-funded Compentence Network Obesity (CNO). He published ~ 235 original research and review articles in the field of obesity research, pathogenesis of adverse fat distribution, insulin resistance, type 2 diabetes and other obesity related diseases. Dr. Blüher has a specific research focus in the study of adipose tissue function including regulation of adipose tissue cellularity and adipokine secretion. He conducted several clinical trials on the effects of pharmacologic interventions to treat diabetes and obesity, different exercise regimens, diet strategies and bariatric surgery.
Dr. Byers is a Professor of Epidemiology and Associate Dean at the Colorado School of Public Health. He has previously served as the Deputy Director and Interim Director of the University of Colorado Comprehensive Cancer Center, where he is now the Associate Director for Cancer Prevention and Control. He is also the Director of the Center for Public Health Practice at the Colorado School of Public Health, where he is developing training and programs to improve the effectiveness of public health systems. He is an expert in the role of early detection, diet, and nutrition in the prevention of cancer, having published over 350 papers in peer-reviewed scientific journals. He is a member of the Board of Directors of the American Cancer Society, and will assume the role of ACS National President in 2014.
Stephen Colagiuri is Professor of Metabolic Health and co-Director of The Boden Institute at the University of Sydney. His research interests focus on development and implementation of evidence-based guidelines, diabetes screening and prevention, and economic aspects of diabetes and obesity. He has over 200 publications in scientific journals and books. He is a past President of the Australian Diabetes Society. He is chair of the International Diabetes Federation Clinical Guidelines Taskforce, an advisor on diabetes to the World Health Organization, and co-Director of The Boden Institute’s WHO Collaborating Centre on Physical Activity, Nutrition and Obesity. He is editor-in-chief of Diabetes Research and Clinical Practice.
Greg Cooney completed his PhD in metabolic biochemistry at Sydney University in 1980 and then spent four years in the Department of Biochemistry at Oxford University with Eric Newsholme working on the role of thermogenic brown adipose tissue in energy balance and obesity. He returned to Sydney in 1985 and worked with animal models of obesity and insulin resistance in the Endocrinology Department at RPAH before joining the Garvan Institute in 1997 to continue studies in obesity, insulin resistance and type 2 diabetes. Greg is an NHMRC Senior Research Fellow and has served as a Senior Editor for the Journal of Endocrinology, an Associate Editor for Diabetologia and is on the Editorial Board of Diabetes and the American Journal of Physiology. Greg was Treasurer on the first Australian and New Zealand Obesity Council and has also been Treasurer and Vice President of the Australian Diabetes Society.
Luc Van Gaal
Luc Van Gaal studied medicine at the University of Antwerp, where he graduated in 1978. He obtained a specialist degree in internal medicine and afterwards in endocrinology and metabolism in 1983. Since then, he has become responsible for the Metabolic Unit at the Antwerp University Hospital. In 1992 he became Professor of Medicine at Antwerp University and is currently head of the department of Endocrinology, Diabetology and Metabolism of the University Hospital. Professor Van Gaal’s main clinical and research interests are related to obesity, type 2 diabetes and lipid metabolism. He is a member of many scientific, national and international societies and a member of the Editorial Board of a series of scientific journals. He is board member of the Belgian Association for the Study of Obesity (BASO) and Past-President of the Belgian Diabetic Society. He is as a founding member also involved in the scientific activities of the Obesitas Forum (Belgium) and the International (IASO) SCOPE programme. He is the running secretary of the Belgian Endocrine Society. In 2000, he was the co-President of the 10th European Congress on Obesity, organized in Antwerp in May 2000. He participated to and/or featured as (country) coordinator or principal investigator a number of clinical (outcome) trials in the field of obesity and diabetes. He has published more than 240 papers in international medical journals, mainly in the areas of general endocrinology, obesity, diabetes and lipids and has contributed to a number of textbooks about obesity.
Ron Grunstein is currently Professor of Sleep Medicine, The University of Sydney and head of the Australian National Health and Medical Research Council (NHMRC) Centre for Integrated Research and Understanding of Sleep (CIRUS) and the Australasian Sleep Trials Network. Professor Grunstein is a staff specialist physician in Respiratory and Sleep Medicine at Royal Prince Alfred Hospital, has an honorary appointment in respiratory and sleep medicine at St Vincent’s Hospital, Sydney and heads the Sleep and Circadian Research Group, Woolcock Institute of Medical Research. Dr Grunstein was awarded the Nathaniel Kleitman Award of the American Academy of Sleep Medicine in 2011 and the Distinguished Achievement Award of the Australasian Sleep Association in 2010. In 2012, he was awarded the RPA Foundation research medal. He has a long standing interest in health communication through the media and in 2008 was appointed a Public Member of the Australian Press Council. Dr Grunstein also serves as chief medical advisor to Sleep Disorders Australia, an advocacy body for patients with sleep disorders. He has also advised Australian, British and EU road regulatory bodies on sleep disorders and has served as Associate Editor of Sleep and a member of the editorial board of the Journal of Sleep Research, Sleep Medicine Reviews, Sleep Medicine and Respiratory Research. He has Bachelor of Medicine and Surgery degrees and a Doctor of Medicine from the University of Sydney and a PhD from the University of Gothenburg, Sweden. Professor Grunstein was the President of the World Sleep Federation (2007-11) that represents over 12,000 researchers and sleep clinicians globally and was President of the Australasian Sleep Association 1994-1997.
Dr. Paul Hockings is an Associate Director in Drug Safety and Metabolism at AstraZeneca. He received his Bachelors degree from the University of Queensland and Ph.D. from Griffith University in Brisbane, Australia. His main area of expertise is the use of medical imaging techniques to develop biomarkers to test novel pharmaceuticals in both the pre-clinical and clinical settings. Research covers a broad range of disease areas including stroke, metabolic disease, atherosclerosis, cardiac function, colitis, chronic obstructive pulmonary disorder and drug safety. A theme has been the use of imaging technologies to reduce animal usage and refine animal experimentation within the pharmaceutical industry. Paul has authored 38 peer reviewed papers and book chapters on a wide range of imaging applications. Prior to joining AstraZeneca Paul worked for GlaxoSmithKline and SmithKline Beecham in the UK.
Professor Karen Lam is Chair Professor and Head in Medicine, Director of the Research Centre on Heart, Brain, Hormone & Healthy Aging, Chairman of Clinical Trial Centre and Clinical Director of the State Key Laboratory of Pharmaceutical Biotechnology (focusing on obesity, diabetes and diabetic complications), at the University of Hong Kong. The Founding President of Diabetes Hong Kong, she was also a president of the HK Endocrine Society and Chairman of two specialty boards of the HK College of Physicians – Advanced Internal Medicine and Endocrinology, Diabetes & Metabolism. Professor Lam has published extensively on clinical, basic and translational research in diabetes and endocrinology, including publications in Diabetes, Diabetes Care, JCEM, ATVB, Circulation, Cell Metabolism, PNAS, JCI and Lancet. Her current research focuses on the role of adipokines in diabetes and other obesity-related cardiometabolic disorders, based in part on two large cohorts with long-term follow-up, the CRISPS and the HKW Diabetes Registry.
Dr Tim Lobstein is Director of Policy and Programmes at the International Association for the Study of Obesity (IASO), London. Dr Lobstein has been the Principle Investigator for several European Commission-funded obesity-related research projects, including POLMARK and STANMARK, concerned with marketing food to children, and is responsible for work packages in EC-funded projects: DYNAMO-HIA, ENERGY, SPOTLIGHT and TOYBOX. Dr Lobstein is an adviser to the World Health Organization on food and nutrition policies, and has held posts as Research Fellow at the University of Sussex Science Policy Research Unit, Rudd Visiting Fellow at Yale University, USA, and is currently an Adjunct Professor of Public Health Advocacy at Curtin University, Western Australia.
Luis A. Moreno is Professor of Public Health at the University of Zaragoza (Spain). He is also Visiting Professor of Excellence at the University of Sao Paulo (Brazil) and affiliated member at the Johns Hopkins Global Center on Childhood Obesity. He did his training as Medical Doctor and his PhD thesis at the University of Zaragoza. He studied Human Nutrition and Public and Community Health at the University of Nancy, FrLuis A. Moreno is Professor of Public Health at the University of Zaragoza (Spain). He is also Visiting Professor of Excellence at the University of Sao Paulo (Brazil) and affiliated member at the Johns Hopkins Global Center on Childhood Obesity. He did his training as Medical Doctor and his PhD thesis at the University of Zaragoza. He studied Human Nutrition and Public and Community Health at the University of Nancy, France. He has participated in several research projects supported by the Spanish Ministry of Health, and the European commission (HELENA, IDEFICS, EURRECCA, ENERGY, ToyBox and iFamily). He has published more than 250 papers in peer reviewed journals. He is the coordinator of the GENUD (Growth, Exercise, Nutrition and Development) research group, at the University of Zaragoza. He is a former member of the ESPGHAN Committee of Nutrition.
Thomas Morley is currently an MSTP graduate student in the Laboratory of Philipp Scherer at the University of Texas Southwestern Medical Center in Dallas. Following his Undergraduate training at the University of Connecticut where he completed dual bachelor’s degrees in chemistry and molecular biology, he went to train at the NIH in Bethesda , MD for two years. Under the guidance of Dr. Stephen Leppla in NIAID, Thomas worked on novel immunotoxin generation using anthrax toxin for the targeting of head and neck squamous cell carcinomas. Following his time at NIH, he began the MD/PhD program at UTSW and is currently under the direction of Dr. Scherer in the Touchstone Diabetes Center. Thomas’ work focuses on inflammation in the breast cancer microenvironment and how this contributes to both tumor initiation and progression.
Angelo Tremblay is currently professor at the Department of Kinesiology at Laval University, Quebec City, from where he obtained his undergraduate (BSc in Education) and postgraduate degrees (MSc in Nutrition and PhD in Physiology) between 1974 and 1982. Dr. Tremblay's department has an international reputation in obesity research and his own particular interests are focused primarily on the environmental determinants of obesity in humans. He has published over 550 scientific papers. He is holder of the Canada Research Chair in Environment and Energy Balance.